Rapt Therapeutics cuts staff for 2nd time in less than a year, continuing fallout from FDA hold
Rapt Therapeutics has conducted its second round of layoffs in just under a year, continuing a period of upheaval following the clinical hold—and eventual discontinuation—of the immunology biotech’s former lead asset.
Rapt Therapeutics has conducted its second round of layoffs in just under a year, continuing a period of upheaval following the clinical hold—and eventual discontinuation—of the immunology biotech’s former lead asset.
